Biliary Cystadenocarcinoma
Biliary cystadenocarcinoma is a rare malignant cystic tumor of the liver or biliary tract, considered the cancerous counterpart of biliary cystadenoma (mucinous cystic neoplasm). It often arises in a preexisting cystadenoma and shares many features with it, but contains malignant cells with invasive potential. Most are diagnosed in middle-aged or older adults, with the average age slightly higher than for benign cystadenomas. Complete surgical resection is the cornerstone of treatment when feasible, and outcomes are generally more favorable than for many other biliary cancers when the tumor is identified early and fully removed.
What is it?
Biliary cystadenocarcinoma is a rare malignant cystic tumor of the liver or biliary tract. In modern pathology classifications, these tumors are generally considered invasive carcinomas arising within a mucinous cystic neoplasm (MCN) of the liver. Historically, they were referred to as the malignant counterpart of biliary cystadenoma. Some tumors appear to arise through malignant transformation of a preexisting mucinous cystic neoplasm over time, although not all cases demonstrate a clearly identifiable benign precursor lesion.
The tumor typically appears as a complex cystic mass with thickened walls, multiple internal compartments (septations), mural nodules or solid components, and—in many cases—features suggesting invasive growth into surrounding tissue.
Biliary cystadenocarcinomas are most often diagnosed in middle-aged or older adults. They have historically been reported more frequently in women, although important pathological differences exist between tumor subtypes. Tumors containing the characteristic ovarian-type stroma are seen almost exclusively in women and correspond to mucinous cystic neoplasms under current World Health Organization (WHO) classification criteria. Tumors lacking ovarian-type stroma may occur more commonly in men and may represent a somewhat different biological entity. The right lobe of the liver is involved more often than the left, but the tumor can develop throughout the liver or biliary system.
The cause of biliary cystadenocarcinoma is not fully understood. Some cases appear to arise through progressive genetic and cellular changes within a preexisting mucinous cystic neoplasm, similar to the adenoma-to-carcinoma sequence recognized elsewhere in the gastrointestinal tract. The condition is unrelated to common simple hepatic cysts and polycystic liver disease.
Symptoms vary depending on the size and location of the tumor. Many lesions are large at the time of diagnosis. Common symptoms include upper right abdominal pain or fullness, a palpable mass, early fullness with meals, nausea, fatigue, and unintentional weight loss. Tumors near the major bile ducts may cause jaundice, dark urine, pale stools, and itching. Less commonly, bleeding within the cyst, infection of cyst contents, or rupture may occur.
Diagnosis combines clinical assessment, imaging, and pathology. Imaging often raises strong suspicion when a complex cystic liver lesion demonstrates thickened or irregular walls, multiple internal septations with nodular thickening, solid enhancing components, calcifications, growth over time, or invasion of surrounding structures. Ultrasound, CT with contrast, MRI with contrast, and MRCP all play important roles, with MRI typically providing the most detailed characterization of the lesion and biliary anatomy. Tumor markers such as CA 19-9 and CEA may be elevated in some patients, although they are neither sufficiently sensitive nor specific to establish the diagnosis and should be interpreted alongside imaging and pathology findings. Endoscopic ultrasound and ERCP may be used in selected cases. For most lesions suspicious for mucinous cystic neoplasm or biliary cystadenocarcinoma, definitive diagnosis is usually achieved through complete surgical resection, which permits full pathological evaluation of the lesion.
Important to Know
The cornerstone of treatment for biliary cystadenocarcinoma is complete surgical resection whenever feasible. Because these tumors are rare and lie within the spectrum of mucinous cystic neoplasms of the liver, care is best delivered in centers with hepatobiliary surgical expertise and multidisciplinary teams that may include hepatobiliary surgeons, medical and radiation oncologists, hepatologists, interventional radiologists, pathologists, and palliative care specialists.
Surgical options depend on the size, location, and extent of the tumor. Liver resection—removing a segment, multiple segments, or a lobe of the liver containing the tumor—is the most common approach and offers the best chance for long-term control or cure. Tumors involving the major bile ducts may require more complex hepatobiliary reconstruction. Simple drainage or partial removal is not adequate because of the high risk of recurrence and the possibility of leaving behind malignant tissue.
When complete resection is achieved with clear margins before metastatic spread develops, prognosis is generally more favorable than that seen with conventional cholangiocarcinoma. Long-term outcomes depend on tumor stage, depth of invasion, lymph node involvement, and margin status.
Adjuvant chemotherapy after surgery may be considered in selected patients, guided by pathology findings and principles used for biliary tract cancers. For advanced or unresectable disease, treatment is often extrapolated from cholangiocarcinoma and other biliary tract cancers because prospective studies specific to biliary cystadenocarcinoma are limited. Options may include systemic chemotherapy, targeted therapies, immunotherapy based on molecular profiling, radiation therapy, and locoregional treatments such as transarterial chemoembolization or radioembolization. Clinical trial participation should be considered whenever available given the rarity of this tumor.